Illinois Municipal Retirement Fund Has $6.11 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Illinois Municipal Retirement Fund decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 42.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,015 shares of the company’s stock after selling 8,223 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in IDEXX Laboratories were worth $6,114,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new stake in IDEXX Laboratories during the third quarter worth about $25,000. Valley National Advisers Inc. boosted its position in shares of IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after acquiring an additional 22 shares in the last quarter. Geo Capital Gestora de Recursos Ltd acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth approximately $28,000. Covestor Ltd increased its stake in IDEXX Laboratories by 71.8% in the third quarter. Covestor Ltd now owns 67 shares of the company’s stock valued at $29,000 after acquiring an additional 28 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its stake in IDEXX Laboratories by 108.6% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 73 shares of the company’s stock worth $32,000 after purchasing an additional 38 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, SVP George Fennell sold 8,198 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at approximately $3,851,815.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total value of $6,871,320.00. Following the completion of the transaction, the chief executive officer now directly owns 79,247 shares of the company’s stock, valued at approximately $45,377,624.67. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP George Fennell sold 8,198 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares of the company’s stock, valued at approximately $3,851,815.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,524 shares of company stock valued at $24,871,960. Insiders own 2.18% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on IDXX shares. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. JPMorgan Chase & Co. upped their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. The Goldman Sachs Group upped their price target on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Piper Sandler downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a research report on Tuesday, January 30th. Finally, Barclays upped their target price on IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $591.50.

IDEXX Laboratories Trading Up 3.0 %

IDXX opened at $493.80 on Wednesday. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The firm has a market capitalization of $41.01 billion, a PE ratio of 49.04, a P/E/G ratio of 3.69 and a beta of 1.26. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17. The company’s 50-day moving average is $535.07 and its 200 day moving average is $510.61.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.20. The business had revenue of $901.60 million for the quarter, compared to analysts’ expectations of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The business’s revenue was up 8.8% on a year-over-year basis. During the same period last year, the business earned $2.05 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.